Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study

Lalit Kumar,Sameer Melinkeri, Prasanth Ganesan,Jeevan Kumar,Ghanashyam Biswas,Nalini Kilara, Harish Pathalingappa, S. V. S. S. Prasad,Minish Jain,Sourav Kumar Mishra, Saurabh Prasad,Pavan Kumar Boyella,Ranjit Kumar Sahoo,Shailesh Bondarde,Sandip Shah, Milind Rege,Uttiya Deb, Tanuja Korde, Jitendra Dixit

FUTURE ONCOLOGY(2024)

引用 0|浏览3
暂无评分
摘要
Aim: To assess the safety and effectiveness of daratumumab monotherapy in Indian patients with relapsed/refractory multiple myeloma. Methods: In this prospective, multicenter, phase IV study, patients (aged >= 18 years) received intravenous daratumumab (16 mg/kg) in six cycles. Safety was the primary end point. Results: Of the 139 patients included, 121 (87.1%) experienced >= 1 treatment-emergent adverse events (TEAEs; 53 [38.1%] drug-related), 32 (23%) had >= 1 serious TEAEs (five [3.6%] drug-related) and 16 (11.5%) deaths were reported (one death [0.7%] was drug-related). Overall response rate was 26.3%; 62.7% of patients had stable disease. Median time to first response and median progression-free survival were 5.2 and 5.9 months, respectively. Functional status and well-being were improved. Conclusion: Daratumumab showed an acceptable and expected safety profile with consistent efficacy, providing a novel therapeutic option for relapsed/refractory multiple myeloma management in India. Daratumumab is a monoclonal antibody approved for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). This study evaluated the outcome of daratumumab single therapy in Indian patients who were not cured with other drugs used for the same disease. 139 adult patients were included in this study from 15 institutes across India. Daratumumab (16 mg/kg) was diluted with 500 or 1000 ml of saline solution and given slowly through the intravenous route 16-times within 6 months. The study examined whether the safety profile and benefits of daratumumab reported in Indian patients were similar to those reported in the RRMM populations of other countries. The study found that most of the adverse events were not severe and could be easily treated by the study physician. 16 patients died (one might have been due to daratumumab treatment). Daratumumab treatment provided life support and recovery benefits to many patients. Daratumumab single therapy provides an appropriate and acceptable safety profile with no new adverse events and consistent benefits in RRMM patients.Clinical Trial Registration: NCT03768960 (ClinicalTrials.gov), CTRI/2019/06/019546. This study demonstrated an acceptable and expected safety profile with consistent efficacy for daratumumab monotherapy in patients with relapsed/refractory multiple myeloma, providing a novel therapeutic option for myeloma management in India.
更多
查看译文
关键词
adverse event,clinical response,daratumumab,multiple myeloma,overall response rate
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要